Skip to main content

Apixaban Disease Interactions

There are 3 disease interactions with apixaban.

Major

Factor Xa inhibitors (applies to apixaban) bleeding

Major Potential Hazard, Moderate plausibility.

The use of factor Xa inhibitors is contraindicated in patients with active pathological bleeding. Its use increases the risk of bleeding and can cause serious or fatal bleeding. Caution is recommended when prescribing these agents to patients at increased risk of bleeding. When using these agents, the risk of thrombotic events should be weighed against the risk of bleeding.

References

  1. "Product Information. Arixtra (fondaparinux)." Organon (2002):
  2. "Product Information. Xarelto (rivaroxaban)." Bayer Inc (2008):
  3. "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb Canada Inc (2012):
  4. "Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc. (2015):
View all 4 references
Major

Factor Xa inhibitors (applies to apixaban) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

In general, the manufacturer recommends avoiding the use of factor Xa inhibitors in patients with moderate and severe hepatic impairment or with any hepatic disease associated with coagulopathy as drug exposure and bleeding risk may be increased.

References

  1. "Product Information. Arixtra (fondaparinux)." Organon (2002):
  2. "Product Information. Xarelto (rivaroxaban)." Bayer Inc (2008):
  3. "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb Canada Inc (2012):
  4. "Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc. (2015):
View all 4 references
Major

Factor Xa inhibitors (applies to apixaban) valvular heart disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Prosthetic Heart Valves

The use of factor Xa inhibitors is not recommended in patients with prosthetic heart valves as no studies have been conducted for safety and efficacy.

References

  1. "Product Information. Arixtra (fondaparinux)." Organon (2002):
  2. "Product Information. Xarelto (rivaroxaban)." Bayer Inc (2008):
  3. "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb Canada Inc (2012):
  4. "Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc. (2015):
View all 4 references

Apixaban drug interactions

There are 341 drug interactions with apixaban.


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.